Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. This news page aggregates company press releases and third-party coverage related to MRKR, with a focus on clinical data, research milestones, and corporate developments.
Investors and followers of MRKR can review updates on the company’s lead program, MT-601, a MAR-T cell product being evaluated in the Phase 1 APOLLO trial for patients with relapsed or refractory lymphoma who have failed or are not candidates for anti-CD19 CAR-T cell therapy. News items include reported objective response rates, safety findings such as the absence of dose-limiting toxicities and ICANS in dose escalation cohorts, and progress into dose expansion in diffuse large B cell lymphoma.
Coverage also highlights Marker’s expansion into additional indications, including a pancreatic cancer program supported by non-dilutive funding and an Off-the-Shelf MAR-T initiative, MT-401-OTS, in the RAPID trial for relapsed acute myeloid leukemia or myelodysplastic syndromes. Readers will find announcements on first-patient dosing, early safety observations, and scientific insights such as the impact of lymphodepletion on MAR-T cell expansion and persistence.
Beyond clinical results, MRKR news includes financial updates, grant awards from U.S. state and federal agencies, collaborations such as the cGMP manufacturing agreement with Cellipont Bioservices for MT-601, participation in investor conferences, and changes in corporate governance and auditors. This page is a resource for tracking how Marker’s MAR-T platform and pipeline evolve over time.
Marker Therapeutics (MRKR) reported Q3 2024 financial results and business updates. The company received two $2 million NIH SBIR grants to support MT-601 clinical trials in lymphoma and pancreatic cancer patients. The ongoing Phase 1 APOLLO study for MT-601 in lymphoma patients shows promising activity, with preliminary data expected by year-end. Financial highlights include $9 million in cash and cash equivalents, expected to fund operations into October 2025. Q3 2024 showed R&D expenses of $3.5 million, G&A expenses of $0.9 million, and a net loss of $2.3 million.
Marker Therapeutics (Nasdaq: MRKR) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Preliminary safety and efficacy data from the Phase 1 APOLLO study of MT-601 in lymphoma patients showed objective responses in 3 out of 3 participants.
2. MT-601 was well-tolerated with no cytokine release syndrome or neurotoxicity observed.
3. Marker received a $2 million NIH SBIR grant to support MT-601 clinical investigation.
4. Q2 2024 financial results: $7.8 million in cash and cash equivalents, $2.3 million in R&D expenses, $1.1 million in G&A expenses, and a net loss of $2.2 million.
5. The company expects its cash to fund operations into Q4 2025.
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nationwide multi-center Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601, a multi-tumor associated antigen-specific T cell product.
The company has now received over $19 million in non-dilutive funding. Preliminary results from the APOLLO study show objective responses in all three study participants treated at City of Hope, with no cytokine release syndrome or immune effector cell associated neurotoxicity syndrome observed. This grant supports Marker's efforts to address the unmet medical need for patients who relapse after CD19-targeting CAR-T cell therapy.
Marker Therapeutics (Nasdaq: MRKR) reported first quarter 2024 financial results and business updates. The company highlighted continued clinical progress, noting promising results in its Phase 1 APOLLO study of MT-601 for lymphoma. Significant milestones include sustained complete responses in study participants and an official nonproprietary name 'neldaleucel' for MT-601. Financially, Marker saw a reduction in R&D and G&A expenses, narrowing its net loss to $2.4 million from $4.9 million year-over-year. Cash and cash equivalents stood at $11.3 million, expected to fund operations into Q4 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.